Международные клинические рекомендации для практических врачей по диагностике и лечению облитерирующего бронхиолита
https://doi.org/10.18093/0869-0189-2015-25-4-403-424
Аннотация
Синдром облитерирующего бронхиолита (СОБ) – серьезное осложнение трансплантации легких, при котором сокращается выживаемость больных. Международным обществом по трансплантации легких и сердца, Американским торакальным и Европейским респираторным обществами созданы Международный комитет экспертов для разработки клинических рекомендаций по ведению пациентов с СОБ. В этих Рекомендациях дано определение СОБ, описаны факторы риска, диагностика, ведение больных и профилактика СОБ. Для разработки Рекомендаций собрана доказательная информация по СОБ с 1980 г. до марта 2013 г. Комитетом экспертов обсуждались доступные научные доказательства. Оценка Рекомендаций проводилась по системе GRADE. Термин СОБ относится к поздней дисфункции трансплантата с неуклонным снижением объема форсированного выдоха за 1ю секунду, необъяснимое другими причинами. В данных Рекомендациях обсуждаются вопросы использования системных глюкокортикостероидов, циклоспорина, такролимуса, азитромицина и ретрансплантации у больных с предполагаемым и подтвержденным СОБ. В случае диагноза СОБ требуется тщательное исключение других посттрансплантационных осложнений с поздней дисфункцией трансплантата. Выявлено несколько факторов риска, тесно связанных с развитием СОБ. В настоящее время отсутствует лечение, при помощи которого можно бы предотвратить или существенно повлиять на СОБ. Для поиска оптимальных методов лечения и эффективных мер профилактики необходимы хорошо спланированные рандомизированные контролируемые исследования, в которых прослеживались бы все значимые для пациента показатели.
Список литературы
1. Burke C.M., Theodore J., Dawkins K.D. et al. Post transplant obliterative bronchiolitis and other late lung sequelae in human heart lung transplant recipients. Chest. 1984; 86: 824–829.
2. Christie J.D., Edwards L.B., Aurora P. et al. The registry of the International Society for Heart and Lung Transplantation: twenty sixth official adult lung and heart lung transplantation report 2009. J. Heart Lung Trans plant. 2009; 28: 1031–1049.
3. The International Society for Heart and Lung Transplantation. www.ishlt.org
4. Cooper J.D., Billingham M., Egan T. et al. A working for mulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 1993; 12: 713–716.
5. Estenne M., Maurer J.R., Boehler A. et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J. Heart Lung Transplant. 2002; 21: 297–310.
6. Bando K., Paradis I.L., Similo S. et al. Obliterative bronchiolitis after lung and heart lung transplantation. An analysis of risk factors and management. J. Thorac. Cardiovasc. Surg. 1995; 110: 4–13.
7. Reichenspurner H., Girgis R.E., Robbins R.C. et al. Stanford experience with obliterative bronchiolitis after lung and heart lung transplantation. Ann. Thorac. Surg. 1996; 62: 1467–1472.
8. Kramer M.R., Stoehr C., Whang J.L. et al. The diagnosis of obliterative bronchiolitis after heart lung and lung transplantation: low yield of transbronchial lung biopsy. J. Heart Lung Transplant. 1993; 12: 675–681.
9. Pomerance A., Madden B., Burke M.M. et al. Transbronchial biopsy in heart and lung transplantation: clinicopathologic correlations. J. Heart Lung Transplant. 1995; 14: 761–773.
10. Chamberlain D., Maurer J., Chaparro C. et al. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J. Heart Lung Transplant. 1994; 13: 963–971.
11. Burton C.M., Iversen M., Carlsen J. et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post transplant baseline FEV1. J. Heart Lung Transplant. 2009; 28: 888–893.
12. Schulman L.L., Weinberg A.D., McGregor C. et al. Mis matches at the HLA DR and HLA B loci are risk factors for acute rejection after lung transplantation. Am. J. Respir. Crit. Care Med. 1998; 157: 1833–1837.
13. Burlingham W.J., Love R.B., Jankowska Gan E. et al. IL 17 dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Invest. 2007; 117: 3498–3506.
14. Belperio J.A., Weigt S., Fishbein M.C. et al. Chronic lung allograft rejection: mechanisms and therapy. Proc. Am. Thorac. Soc. 2009; 6: 108–121.
15. Weigt S.S., Wallace W.D., Derhovanessian A. et al. Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment. Semin. Respir. Crit. Care Med. 2010; 31: 189–207.
16. Verleden G.M., Vos R., De Vleeschauwer S.I. et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl. Int. 2009; 22: 771–779.
17. Schünemann H.J., Jaeschke R., Cook D.J. et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am. J. Respir. Crit. Care Med. 2006; 174: 605–614.
18. Sato M., Waddell T.K., Wagnetz U. et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J. Heart Lung Transplant. 2011; 30: 735–742.
19. Lama V.N., Murray S., Lonigro R.J. et al. Course of FEV1 after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am. J. Respir. Crit. Care Med. 2007; 175: 1192–1198.
20. Woodrow J.P., Shlobin O.A., Barnett S.D. et al. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J. Heart Lung Transplant. 2010; 29:
21. –1164.
22. Jackson C.H., Sharples L.D., McNeil K. et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J. Heart Lung Transplant. 2002; 21: 658–666.
23. Brugière O., Pessione F., Thabut G. et al. Bronchiolitis obliterans syndrome after single lung transplantation: impact of time to onset on functional pattern and survival. Chest. 2002; 121: 1883–1889.
24. Burton C.M., Carlsen J., Mortensen J. et al. Long term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 2007; 26: 681–686.
25. Nathan S.D., Ross D.J., Belman M.J. et al. Bronchiolitis obliterans in single lung transplant recipients. Chest. 1995; 107: 967–972.
26. Vos R., Vanaudenaerde B.M., Ottevaere A. et al. Long term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J. Heart Lung Transplant. 2010; 29: 1358–1368.
27. Gottlieb J., Szangolies J., Koehnlein T. et al. Long term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008; 85: 36–41.
28. Vos R., Vanaudenaerde B.M., Verleden S.E. et al. A randomised controlled trial of azithromycin to prevent bronchiolitis obliterans syndrome after lung transplantation. Eur. Respir. J. 2011; 37: 164–172.
29. Stewart S., Fishbein M.C., Snell G.I. et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J. Heart Lung Transplant. 2007; 26: 1229–1242.
30. Keller C.A., Cagle P.T., Brown R.W. et al. Bronchiolitis obliterans in recipients of single, double, and heart lung transplantation. Chest. 1995; 107: 973–980.
31. Girgis R.E., Tu I., Berry G.J. et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J. Heart Lung Transplant. 1996; 15: 1200–1208.
32. Kroshus T.J., Kshettry V.R., Savik K. et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J. Thorac. Cardiovasc. Surg. 1997; 114: 195–202.
33. Heng D., Sharples L.D., McNeil K. et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J. Heart Lung Transplant. 1998; 17: 1255–1263.
34. Husain A.N., Siddiqui M.T., Holmes E.W. et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med.1999; 159: 829–833.
35. El Gamel A., Sim E., Hasleton P. et al. Transforming growth factor beta (TGF β) and obliterative bronchilitis following pulmonary transplantation. J. Heart Lung Trans plant. 1999; 18: 828–837.
36. Sharples L.D., McNeil K., Stewart S. et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J. Heart Lung Transplant. 2002; 21: 271–281.
37. Burton C.M., Iversen M., Scheike T. et al. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J. Heart Lung Transplant. 2008; 27: 1128–1134.
38. Glanville A.R., Aboyoun C.L., Havryk A. et al. Severity of lymphocytic bronchiolitis predicts long term outcome after lung transplantation. Am. J. Respir. Crit. Care Med. 2008; 177: 1033–1040.
39. Ross D.J., Marchevsky A., Kramer M. et al. "Refractoriness" of airflow obstruction associated with isolated lymphocytic bronchiolitis / bronchitis in pulmonary allografts. J. Heart Lung Transplant. 1997; 16: 832–838.
40. Guilinger R.A., Paradis I.L., Dauber J.H. et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am. J. Respir. Crit. Care Med. 1995; 152: 2037–2043.
41. Levine S.M., Transplant / Immunology Network of the American College of Chest. Physicians. A survey of clinical practice of lung transplantation in North America. Chest. 2004; 125: 1224–1238.
42. Hopkins P.M., Aboyoun C.L., Chhajed P.N. et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am. J. Respir. Crit. Care Med. 2004; 170: 1022–1026.
43. Hachem R.R., Khalifah A.P., Chakinala M.M. et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005; 80: 1406–1413.
44. Khalifah A.P., Hachem R.R., Chakinala M.M. et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am. J. Transplant. 2005; 5: 2022–2030.
45. Palmer S.M., Davis R.D., Hadjiliadis D. et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002; 74: 799–804.
46. Lau C.L., Palmer S.M., Posther K.E. et al. Influence of panel reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann. Thorac. Surg. 2000; 69: 1520–1524.
47. Girnita A.L., Duquesnoy R., Yousem S.A. et al. HLA specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am. J. Transplant. 2005; 5: 131–138.
48. Sundaresan S., Mohanakumar T., Smith M.A. et al. HLA A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplanta tion. 1998; 65: 648–653.
49. Jaramillo A., Smith M.A., Phelan D. et al. Development of ELISA detected anti HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation. 1999; 67: 1155–1161.
50. Bharat A., Narayanan K., Street T. et al. Early posttrans plant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation. 2007; 83: 150–158.
51. Bharat A., Kuo E., Steward N. et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann. Thorac. Surg. 2008; 86: 189–195.
52. Daud S.A., Yusen R.D., Meyers B.F. et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 2007; 175: 507–513.
53. Huang H.J., Yusen R.D., Meyers B.F. et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am. J. Transplant. 2008; 8: 2454–2462.
54. Botha P., Archer L., Anderson R.L. et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008; 85: 771–774.
55. Vos R., Vanaudernaerde B.M., De Vleeschauwer S.I. et al. De novo or persistent pseudomonal airway colonization after lung transplantation: importance for bronchiolitis obliterans syndrome? Transplantation. 2008; 86: 624–625.
56. Gottlieb J., Mattner F., Weissbrodt H. et al. Impact of graft colonization with Gram negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir. Med. 2009; 103: 743–749.
57. Keenan R.J., Lega M.E., Dummer J.S. et al. Cytomega lovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991; 51: 433–438.
58. Smith M.A., Sundaresan S., Mohanakumar T. et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis syndrome. J. Thorac. Cardiovasc. Surg. 1998; 116; 812–820.
59. Engelmann I., Welte T., Fühner T. et al. Detection of Epstein Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J. Clin. Virol. 2009; 45: 47–53.
60. Kumar D., Erdman D., Keshavjee S. et al. Clinical impact of community acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am. J. Transplant. 2005; 5: 2031–2036.
61. Bridges N.D., Spray T.L., Collins M.H. et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J. Thorac. Cardiovasc. Surg. 1998; 116: 617–623.
62. Khalifah A.P., Hachem R.R., Chakinala M.M. et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am. J. Respir. Crit. Care Med. 2004; 170: 181–187.
63. Billings J.L., Hertz M.I., Savik K. et al. Respiratory viruses and chronic rejection in lung transplant recipients. J. Heart Lung Transplant. 2002; 21: 559–566.
64. Vilchez R.A., Dauber J., McCurry K. et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am. J. Transplant. 2003; 3: 116–120.
65. Palmer S.M. Jr, Henshaw N.G., Howell D.N. et al. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998; 113: 944–950.
66. D, Ovidio F., Singer L.G., Hadjiliadis D. et al. Prevalence of gastroesophageal reflux in end stage lung disease candidates for lung transplant. Ann. Thorac. Surg. 2005; 80: 1254–1260.
67. Blondeau K., Mertens V., Vanaudenaerde B.A. et al. Gastrooesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur. Respir. J. 2008; 31: 707–713.
68. King B.J., Iyer H., Leidi A.A. et al. Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective. J. Heart Lung Transplant. 2009; 28: 870–875.
69. Hadjiliadis D., Duane Davis R., Steele M.P. et al. Gastroesophageal reflux disease in lung transplant recipients. Clin. Transplant. 2003; 17: 363–368.
70. Valentine V.G., Gupta M.R., Walker J.E. Jr et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 2009; 28: 163–169.
71. Weigt S.S., Elashoff R.M., Huang C. et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am. J. Transplant. 2009; 9: 1903–1911.
72. Weigt S.S., Copeland C.A., Derhovanessian A. et al. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two center validation study. Am. J. Transplant. 2013; 13: 919–927.
73. Gandhi M.K., Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 2004; 4: 725–738.
74. Ibrahim L., Dominguez M., Yacoub M. Primary human adult lung epithelial cells in vitro: response to interferon γ and cytomegalovirus. Immunology. 1993; 79: 119–124.
75. Geist L.J., Dai L.Y. Cytomegalovirus modulates interleukin 6 gene expression. Transplantation. 1996; 62: 653–658.
76. Vos R., Vanaudenaerde B.M., Dupont L.J. et al. Transient airway colonization is associated with airway inflammation after lung transplantation. Am. J. Transplant. 2007; 7: 1278–1287.
77. Bobadilla J.L., Jankowska Gan E., Xu Q. et al. Reflux induced collagen type V sensitization: potential mediator of bronchiolitis obliterans syndrome. Chest. 2010; 138: 363–370.
78. Saini D., Weber J., Ramachandran S. et al. Alloimmunity induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J. Heart Lung Transplant. 2011; 30: 624–631.
79. Henke J.A., Golden J.A., Yelin E.H. et al. Persistent increase of BAL neutrophils as a predictor of mortality following lung transplant. Chest. 1999; 115: 403–409.
80. Meyer K.C., Nunley D.R., Dauber J.H. et al. Neutrophils, unopposed neutrophil elastase, and a1 antiprotease defenses following human lung transplantation. Am. J. Respir. Crit. Care Med. 2001; 164: 97–102.
81. Reynaud Gaubert M., Marin V., Thirion X. et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post transplant airway obliteration. J. Heart Lung Transplant. 2002; 21: 721–730.
82. DiGiovine B., Lynch J.P. 3rd, Martinez F.J. et al. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL 8. J. Immunol. 1996; 157: 4194–4202.
83. Neurohr C., Huppmann P., Leuchte H. et al. Human her pesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am. J. Transplant. 2005; 5: 2982–2991.
84. Schloma J., Slebos D.J., Boezen H.M. et al. Eosinophilic granulocytes and interleukin 6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am. J. Respir. Crit. Care Med. 2000; 162: 2221–2225.
85. Lama V.N., Murray S., Mumford J.A. et al. Prognostic value of bronchiolitis obliterans syndrome stage 0p in singlelung transplant recipients. Am. J. Respir. Crit. Care Med. 2005; 172: 379–383.
86. Hachem R.R., Chakinala M.M., Yusen R.D. et al. The predictive value of bronchiolitis obliterans syndrome stage 0 p. Am. J. Respir. Crit. Care Med. 2004; 169: 468–472.
87. Nathan S.D., Barnett S.D., Wohlrab J. et al. Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients. J. Heart Lung Transplant. 2003; 22: 427–432.
88. Morrish W.F., Herman S.J., Weisbrod G.L. et al. Bronchiolitis obliterans after lung transplantation: findings at chest radiography and high resolution CT. The Toronto Lung Transplant Group. Radiology. 1991; 179: 487–490.
89. Kundu S., Herman S.J., Larhs A. et al. Correlation of chest radiographic findings with biopsyproven acute lung rejection. J. Thorac. Imaging. 1999; 14: 178–184.
90. Collins J. Imaging of the Chest. after lung transplantation. J. Thorac. Imaging. 2002; 17: 102–112.
91. Leung A.N., Fisher K., Valentine V. et al. Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. Chest. 1998; 113: 365–370.
92. Bankier A.A., Van Muylem A., Knoop C. et al. Bronchiolitis obliterans syndrome in heart lung transplant recipients: diagnosis with expiratory CT. Radiology. 2001; 218: 533–539.
93. Lee E.S., Gotway M.B., Reddy G.P. et al. Early bronchiolitis obliterans following lung transplantation: accuracy of expiratory thinsection CT for diagnosis. Radiology. 2000; 216: 472–477.
94. Berstad A.E., Aaløkken T.M., Kolbenstvedt A. et al. Performance of longterm CT monitoring in diagnosing bronchiolitis obliterans after lung transplantation. Eur. J. Radiol. 2006; 58: 124–131.
95. Konen E., Gutierrez C., Chaparro C. et al. Bronchiolitis obliterans syndrome in lung transplant recipients: can thinsection CT findings predict disease before its clinical appearance? Radiology. 2004; 231: 467–473.
96. Tepper R.S., Reister T. Forced expiratory flows and lung volumes in normal infants. Pediatr. Pulmonol. 1993; 15: 357–361.
97. Castile R., Filbrun D., Flucke R. et al. Adult type pulmonary function tests in infants without respiratory disease. Pediatr. Pulmonol. 2000; 30: 215–227.
98. Siegel M.J., Bhalla S., Gutierrez F.R. et al. Post lung transplantation bronchiolitis obliterans syndrome: usefulness of expiratory thinsection CT for diagnosis. Radio logy. 2001; 220: 455–462.
99. Buttgereit F., da Silva J.A., Boers M. et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 2002; 61: 718–722.
100. Ross D.J., Lewis M.I., Kramer M. et al. FK 506 "rescue" immunosuppression for obliterative bronchiolitis after lung transplantation. Chest. 1997; 112: 1175–1179.
101. Borro J.M., Bravo C., Solè A. et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. Transplant. Proc. 2007; 39: 2416–2419.
102. Knoop C., Antoine M., Vachièry J.L. et al. FK 506 rescue therapy for irreversible airway rejection in heart lung transplant recipients: report on five cases. Transplant. Proc. 1994; 26: 3240–3241.
103. Reichenspurner H., Meiser B.M., Kur F. et al. First experience with FK 506 for treatment of chronic pulmonary rejection. Transplant. Proc. 1995; 27: 2009.
104. Kesten S., Chaparro C., Scavuzzo M. et al. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 1997; 16: 905–912.
105. Mentzer R.M. Jr, Jahania M.S., Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation. 1998; 65: 109–113.
106. Revell M.P., Lewis M.E., Llewellyn Jones C.G. et al. Conservation of small airway function by tacrolimus / cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J. Heart Lung Transplant. 2000; 19: 1219–1223.
107. Fieguth H.G., Krueger S., Wiedenmann D.E. et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. Transplant. Proc. 2002; 34: 1884.
108. Cairn J., Yek T., Banner N.R. et al. Time related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 2003; 22: 50–57.
109. Sarahrudi K., Estenne M., Corris P. et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J. Thorac. Cardiovasc. Surg. 2004; 127: 1126–1132.
110. Webster A., Woodroffe R.C., Taylor R.S. et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst. Rev. 2005; 4: CD003961.
111. Gerhardt S.G., McDyer J.F., Girgis R.E. et al. Mainte nance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am. J. Respir. Crit. Care Med. 2003; 168: 121–125.
112. Verleden G.M., Dupont L.J. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004; 77: 1465–1467.
113. Yates B., Murphy D.M., Forrest I.A. et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 2005; 172: 772–775.
114. Shitrit D., Bendayan D., Gidon S. et al. Long term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J. Heart Lung Transplant. 2005; 24: 1440–1443.
115. Verleden G.M., Vanaudenaerde B.M., Dupont L.J. et al. Azithromycin reduces airway neutrophilia and interleukin 8 in patients with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 2006; 174: 566–570.
116. Porhownik N.R., Batobara W., Kepron W. et al. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Can. Respir. J. 2008; 15: 199–202.
117. Jain R., Hachem R.R., Morrell M.R. et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 2010; 29: 531–537.
118. Panpanich R., Lerttrakarnnon P., Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst. Rev. 2008; 1: CD001954.
119. Svanström H., Pasternak B., Hviid A. Use of azithromycin and death from cardiovascular causes. N. Engl. J. Med. 2013; 368: 1704–1712.
120. US Food and Drug Administration. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. www.fda.gov/drugs/drugsafety/ucm341822.htm Date last accessed: September 11, 2013. Date last updated: March 18, 2013.
121. Albert R.K., Connett J., Bailey W.C. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689–698.
122. Young L.R., Hadjiliadis D., Davis R.D. et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest. 2003; 124: 1689–1693.
123. Sweet M.P., Patti M.G., Leard L.E. et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J. Thorac. Cardiovasc. Surg. 2007; 133: 1078–1084.
124. Linden P.A., Gilbert R.J., Yeap B.Y. et al. Laparoscopic fundoplication in patients with end stage lung disease awaiting transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131: 438–446.
125. Gasper W.J., Sweet M.P., Hoopes C. et al. Antireflux surgery for patients with end stage lung disease before and after lung transplantation. Surg. Endosc. 2008; 22: 495–500.
126. Benden C., Aurora P., Curry J. et al. High prevalence of gastroesophageal reflux disease in lung transplant recipients. Pediatr. Pulmonol. 2005; 40: 68–71.
127. O'Halloran E.K., Reynolds J.D., Lau C.L. et al. Laparoscopic Nissen fundoplication for treating reflux in lung transplant recipients. J. Gastrointest. Surg. 2004; 8: 132–137.
128. Davis R.D. Jr, Lau C.L., Eubanks S. et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J. Thorac. Cardiovasc. Surg. 2003; 125: 533–542.
129. Cantu E. 3rd, Appel J.Z. 3rd, Hartwig M.G. et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann. Thorac. Surg. 2004; 78: 1142–1151.
130. Davis C.S., Gagermeier J., Dilling D. et al. A review of the potential applications and controversies of non invasive testing for biomarkers of aspiration in the lung transplant population. Clin. Transplant. 2010; 24: E54–E61.
131. D, Ovidio F., Mura M., Tsang M. et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J. Thorac. Cardiovasc. Surg. 2005; 129: 1144–1152.
132. Hopkins P.M., Kermeen F., Duhig E. et al. Oil red O stain of alveolar macrophages is an effective screening test for gastroesophageal reflux disease in lung transplant recipients. J. Heart Lung Transplant. 2010; 29: 859–864.
133. Lau C.L., Palmer S.M., Howell D.N. et al. Laparoscopic antireflux surgery in the lung transplant population. Surg. Endosc. 2002; 16: 1674–1678.
134. Zheng C., Kane T.D., Kurland G. et al. Feasibility of laparoscopic Nissen fundoplication after pediatric lung or heartlung transplantation: should this be the standard? Surg. Endosc. 2011; 25: 249–254.
135. Burton P.R., Button B., Brown W. et al. Medium term outcome of fundoplication after lung transplantation. Dis. Esophagus. 2009; 22: 642–648.
136. Fisichella P.M., Davis C.S., Gagermeier J. et al. Laparo scopic antireflux surgery for gastroesophageal reflux disease after lung transplantation. J. Surg. Res. 2011; 170: e279–e286.
137. Hartwig M.G., Anderson D.J., Onaitis M.W. et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann. Thorac. Surg. 2011; 92: 462–468.
138. Hoppo T., Jarido V., Pennathur A. et al. Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end stage lung disease before and after lung transplantation. Arch. Surg. 2011; 146: 1041–1047.
139. Fisichella P.M., Davis C.S., Lundberg P.W. et al. The protective role of laparoscopic antireflux surgery against aspiration of pepsin after lung transplantation. Surgery. 2011; 150: 598–606.
140. Wang Z., Zheng Q., Jin Z. Meta analysis of robot assisted versus conventional laparoscopic Nissen fundoplication for gastro oesophageal reflux disease. ANZ J. Surg. 2012; 82: 112–117.
141. Khatri K., Sajid M.S., Brodrick R. et al. Laparoscopic Nissen fundoplication with or without short gastric vessel division: a meta analysis. Surg. Endosc. 2012; 26: 970–978.
142. Brugière O., Thabut G., Castier Y. et al. Lung retransplantation for bronchiolitis obliterans syndrome: long term follow up in a series of 15 recipients. Chest. 2003; 123: 1832–1837.
143. Strueber M., Fischer S., Gottlieb J. et al. Long term out come after pulmonary retransplantation. J. Thorac. Cardiovasc. Surg. 2006; 132: 407–412.
144. Aigner C., Jaksch P., Taghavi S. et al. Pulmonary retransplantation: is it worth the effort? A long term analysis of 46 cases. J. Heart Lung Transplant. 2008; 27: 60–65.
145. Osaki S., Maloney J.D., Meyer K.C. et al. Redo lung transplantation for acute and chronic lung allograft failure: longterm follow up in a single center. Eur. J. Cardiothorac. Surg. 2008; 34: 1191–1197.
146. Novick R.J., Stitt L., Schäfers H.J. et al. Pulmonary retransplantation: does the indication for operation influence postoperative lung function? J. Thorac. Cardiovasc. Surg. 1996; 112: 1504–1513.
147. Novick R.J., Stitt L.W., Al Kattan K. et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. Ann. Thorac. Surg. 1998; 65: 227–234.
148. Kawut S.M., Lederer D.J., Keshavjee S. et al. Outcomes after lung retransplantation in the modern era. Am. J. Respir. Crit. Care Med. 2008; 177: 114–120.
149. Keshavjee S. Retransplantation of the lung comes of age. J. Thorac. Cardiovasc. Surg. 2006; 132: 226–228.
150. Sato M., Ohmori Matsuda K., Saito T. et al. Time dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS). J. Heart Lung Transplant. 2013; 32: 484–491.
151. Vanaudenaerde B.M., De Vleeschauwer S.I., Vos R. et al. The role of the IL23 / IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am. J. Transplant. 2008; 8: 1911–1920.
152. Serody J.S., Hill G.R. The IL 17 differentiation pathway and its role in transplant outcome. Biol. Blood. Marrow. Transplant. 2012; 18: S56–S61.
153. Shilling R.A., Wilkes D.S. Role of Th17 cells and IL 17 in lung transplant rejection. Semin. Immunopathol. 2011; 33: 129–134.
154. Vanaudenaerde B.M., Verleden S.E., Vos R. et al. Innate and adaptive interleukin 17 producing lymphocytes in chronic inflammatory lung disorders. Am. J. Respir. Crit. Care Med. 2011; 183: 977–986.
155. Afzali B., Lombardi G., Lechler R.I. et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 2007; 148: 32–46.
156. Fan L., Benson H.L., Vittal R. et al. Neutralizing IL 17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am. J. Transplant. 2011; 11: 911–922.
157. Vittal R., Fan L., Greenspan D.S. et al. IL 17 induces type V collagen overexpression and EMT via TGF b dependent pathways in obliterative bronchiolitis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013; 304: L401–L414.
158. Bettelli E., Carrier Y., Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235–238.
159. Neujahr D.C., Larsen C.P. Regulatory T cells in lung transplantation – an emerging concept. Semin. Immunopathol. 2011; 33: 117–127.
160. Tiriveedhi V., Takenaka M., Ramachandran S. et al. T regulatory cells play a significant role in modulating MHC class I antibody induced obliterative airway disease. Am. J. Transplant. 2012; 12: 2663–2674.
161. Shi Q., Cao H., Liu J. et al. CD4+ Foxp3+ regulatory T cells induced by TGF b, IL 2 and all trans retinoic acid attenuate obliterative bronchiolitis in rat trachea transplantation. Int. Immunopharmacol. 2011; 11: 1887–1894.
162. Braun R.K., Molitor Dart M., Wigfield C. et al. Transfer of tolerance to collagen type V suppresses T helper cell 17 lymphocyte mediated acute lung transplant rejection. Transplantation. 2009; 88: 1341–1348.
163. Griffin D.O., Rothstein T.L. Human "orChest.rator" CD11b+ B1 cells spontaneously secrete interleukin 10 and regulate T cell activity. Mol. Med. 2012; 18: 1003–1008.
164. Li W., Bribriesco A.C., Nava R.G. et al. Lung transplant acceptance is facilitated by early events in the graft and is associated with lymphoid neogenesis. Mucosal. Immunol. 2012; 5: 544–554.
165. Ward C., Forrest I.A., Murphy D.M. et al. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax. 2005; 60: 865–871.
166. Hodge S., Holmes M., Banerjee B. et al. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am. J. Transplant. 2009; 9: 727–733.
167. Borthwick L.A., Parker S.M., Brougham K.A. et al. Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation. Thorax. 2009; 64: 770–777.
168. Gardner A., Fisher A.J., Richter C. et al. The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation. Am. J. Pathol. 2012; 180: 2293–2308.
169. Cypel M., Yeung J.C., Hirayama S. et al. Technique for prolonged normothermic ex vivo lung perfusion. J. Heart Lung Transplant. 2008; 27: 1319–1325.
170. Cypel M., Rubacha M., Yeung J. et al. Normothermic ex vivo perfusion revents lung injury compared to extended cold preservation for transplantation. Am. J. Transplant. 2009; 9: 2262–2269.
171. Ingemansson R., Eyjolfsson A., Mared L. et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann. Thorac. Surg. 2009; 87: 255–260.
172. Aigner C., Slama A., Hötzenecker K. et al. Clinical ex vivo lung perfusion – pushing the limits. Am. J. Transplant. 2012; 12: 1839–1847.
173. Zych B., Popov A.F., Stavri G. et al. Early outcomes of bilateral sequential single lung transplantation after ex vivo lung evaluation and reconditioning. J. Heart Lung Transplant. 2012; 31: 274–281.
174. Fisher A.J., Rutherford R.M., Bozzino J. et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am. J. Transplant. 2005; 5: 537–543.
175. Diamond D.A., Michalski J.M., Lynch J.P. et al. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int. J. Radiat. Oncol. Biol. Phys. 1998; 41: 795–800.
176. Benden C., Speich R., Hofbauer G.F. et al. Extracorporeal photopheresis after lung transplantation: a 10 year single center experience. Transplantation. 2008; 86: 1625–1627.
177. Morrell M.R., Despotis G.J., Lublin D.M. et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J. Heart Lung Transplant. 2010; 29: 424–431.
178. Cahill B.C., Somerville K.T., Crompton J.A. et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J. Heart Lung Transplant. 2003; 22: 169–176.
179. Reams B.D., Musselwhite L.W., Zaas D.W. et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am. J. Transplant. 2007; 7: 2802–2808.
180. Shyu S., Dew M.A., Pilewski J.M. et al. Five year out comes with alemtuzumab induction after lung transplantation. J. Heart Lung Transplant. 2011; 30: 743–754.
181. Cai J., Terasaki P.I. Induction immunosuppression improves long term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010; 90: 1511–1515.
Рецензия
Для цитирования:
статья Р. Международные клинические рекомендации для практических врачей по диагностике и лечению облитерирующего бронхиолита. Пульмонология. 2015;25(4):403-424. https://doi.org/10.18093/0869-0189-2015-25-4-403-424
For citation:
article E. International practical guidelines on diagnosis, prevention and treatment of bronchiolitis obliterans syndrome. PULMONOLOGIYA. 2015;25(4):403-424. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-4-403-424
Просмотров: 1293
Послать статью по эл. почте 